Immunology and Microbiology
T Cell
100%
Cytotoxic T-Cell
59%
CD8
50%
Tumor-Infiltrating Lymphocytes
43%
Cell Infiltration
31%
Immunotherapy
26%
Memory T Cell
20%
Nisin
18%
Positron Emission Tomography
18%
Stimulator of Interferon Genes
18%
CXCL13
18%
Transforming Growth Factor Beta
14%
Lymphocyte
12%
Leadership
12%
T Cell Subset
11%
Xenograft
11%
Disease Free Survival
11%
Lantibiotic
10%
Upregulation
10%
Microsatellite Instability
9%
Cell Differentiation
9%
Epithelial Mesenchymal Transition
9%
Precursor
9%
Mismatch Repair
9%
Mutagenesis
9%
T Cell Receptor
9%
Frameshift Mutation
9%
Human Leukocyte Antigen
9%
Cancer Immunotherapy
9%
Lymph Node
9%
Tumor Escape
9%
Natural Killer Cell
9%
Myelin
9%
Neoantigen
9%
Cell Population
9%
B Cell
9%
Tertiary Lymphoid Structure
7%
Immunocompetent Cell
7%
Immune Response
6%
Mutation Rate
6%
Immune Evasion
6%
Medicine and Dentistry
T Cell
47%
Neoplasm
44%
Endometrial Cancer
40%
CD8 Antigen
32%
Cellular Infiltration
29%
Malignant Neoplasm
26%
Ovarian Cancer
20%
Positron Emission Tomography
18%
Tumor Infiltrating Lymphocyte
18%
Zirconium 89
18%
Krukenberg Tumor
18%
Recurrent Disease
12%
T Cell Subset
11%
Immune Checkpoint Blockade
10%
Lymphocyte
10%
DNA Mismatch Repair
10%
Carcinosarcoma
9%
Microsatellite Instability
9%
Endometrium Carcinoma
9%
Frameshift Mutation
9%
Human Leukocyte Antigen
9%
Cervical Cancer
9%
Tumor Microenvironment
9%
Molecular Profiling
9%
Tumor Escape
9%
Interferon
9%
Gallium 68
9%
Natural Killer Cell
9%
T Cell Differentiation
9%
Mesenchymal-Epithelial Transition
9%
Myelin
9%
Sulfatide
9%
B Cell
9%
Uterine Cancer
9%
Cytotoxic T-Cell
9%
Radioactive Tracer
8%
Xenograft
8%
Immunotherapy
7%
Immunocompetent Cell
6%
Neoadjuvant Chemotherapy
6%
T Lymphocyte
6%
Cytoreductive Surgery
6%
Biological Marker
5%
Keyphrases
CD103
35%
Prognostic Benefit
20%
Autoreactive T Cells
19%
T Cell Infiltration
19%
CD8+ T Cells
18%
Tumor-infiltrating Lymphocytes
18%
Nisin
18%
Zirconium-89 (89Zr)
18%
High-grade Serous Ovarian Cancer (HGSOC)
18%
Mismatch Repair
18%
Endometrial Cancer
18%
Tumor
13%
Leader Peptide
10%
Lantibiotics
10%
CD103+ T Cell
10%
Surgical Outcomes
9%
Therapy Response
9%
Treatment Regimen
9%
Human Leukocyte antigen-E
9%
CYP2C9
9%
Intraepithelial T Cells
9%
Tumor Immune Evasion
9%
Proline
9%
Cervical Cancer
9%
Mutagenesis
9%
T Cell Differentiation
9%
Epithelial-mesenchymal Transition
9%
L1 Cell Adhesion Molecule (L1CAM)
9%
Deep Immune Profiling
9%
Neoantigen Load
9%
Uterine Carcinosarcoma
9%
Epithelial Component
9%
STING1
9%
Gallium-68
9%
ImmunoPET
9%
Positron Emission Tomography
9%
CD39
9%
PET Imaging
9%
Non-invasive Assessment
9%
Phenylthiophene
9%
B Cells
9%
Immune Checkpoint Blockade
9%
Phase I Study
9%
Neoadjuvant
9%
T Cells
8%
Resident Memory T Cells
8%
High-grade Serous Epithelial Ovarian Cancer
7%
Neoadjuvant Chemotherapy
6%
CD-8
5%
Pathological Response
5%